

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC
Form 8-K
May 14, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 14, 2003

Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in charter)

| | | |
|---|--|--|
| Delaware (State or other juris- diction of incorporation) | 000-30929 (Commission File Number) | 13-4087132 (IRS Employer Identification No.) |
|---|--|--|

| | |
|--|---------------------|
| 750 Lexington Avenue, 26th Floor New York, NY (Address of principal executive offices) | 10022 (Zip Code) |
|--|---------------------|

Registrant's telephone number, including area code: (212) 531-5965

(Former name or former address, if changed since last report)

Item 9. Regulation FD Disclosure (Information furnished pursuant to Item 12, "Disclosure of Results of Operations and Financial Condition").

On May 14, 2003, Keryx Biopharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with the procedural guidance in SEC Release No. 33-8216, the information in this Form 8-K and the Exhibit attached hereto is being furnished under "Item 9. Regulation FD Disclosure" rather than under "Item 12. Disclosure of Results of Operations and Financial Condition." The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 14, 2003

Keryx Biopharmaceuticals, Inc.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

By: /s/ Michael S. Weiss

Michael S. Weiss

Chairman & Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press release, dated May 14, 2003